A phase 1 and 2, randomized open-label study to evaluate the pharmacokinetics, safety and antiretroviral activity of succinylated human serum albumin (Suc-HSA) in treatment naive HIV-1 infected subjects

Trial Profile

A phase 1 and 2, randomized open-label study to evaluate the pharmacokinetics, safety and antiretroviral activity of succinylated human serum albumin (Suc-HSA) in treatment naive HIV-1 infected subjects

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2015

At a glance

  • Drugs Succinylated human serum albumin (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 13 Nov 2006 Status change
    • 18 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top